InvestorsHub Logo
Followers 25
Posts 676
Boards Moderated 0
Alias Born 08/17/2010

Re: None

Tuesday, 04/17/2012 7:40:03 AM

Tuesday, April 17, 2012 7:40:03 AM

Post# of 81
REPCF is ready for a monster run today!

Are you ready for the next hot one? REPCF - RepliCel Life Sciences Inc. is developing a scientific technology that has the potential to become the world's first, minimally invasive, permanent solution for hair loss in men and women.
That’s why I’m so excited to tell you about this company that provide a very effective solution to hair loss.
The procedure REPCF invented is the one that has been in development over the past nine years by the company's research scientists and medical experts, and is currently undergoing phase I/IIa clinical trials in Europe.
There’s a lot of amazing things going on with REPCF so I'll go straight to the point to keep it from getting too confusing. The potential of this company is enormous, since its technology seems like it is in huge demand today!
I think REPCF is getting the attention of the Street today and you should take a close look at this one immediately.
REPCF is in a huge market!
The American Academy of family Physicians estimates the US market for non-surgical hair treatment s at over $1 Billion annually. This is huge! REPCF is getting the attention of the Street today and I encourage my members to take a close look at this one to be ready for a new action!
Efforts are now focused on ensuring the safety and demonstrating the efficacy of RepliCel’s cell-based hair regeneration procedure in humans. The long-term goal is the development of a safe, evidence-based, minimally invasive procedure to treat various types of hair loss in men and women.
A very impressive management team!
RepliCel was founded by a group of scientists and dermatologists from recognized academic research institutions with experience in immunology, hair biology, hair growth, alopecia, hair follicle endocrinology and morphogenesis, and clinical dermatology. Each scientist holds a long-established track record of research productivity. http://www.replicel.com/our-science/scientific-medical-team/
REPCF was founded to advance the breakthrough findings of Dr. Kevin McElwee and Dr. Rolf Hoffmann, established research scientists in the fields of immunology, hair biology, hair growth, and dermatology. In the early 2000s, at Phillips University in Marburg, Germany, Drs. McElwee and Hoffmann discovered that dermal sheath cup cells have the ability to initiate cellular growth of mature hair follicles in animals. REPCF is now developing this discovery as a potential treatment for hair loss in humans.

In addition to the discovery of the critical cell population, RepliCel has created a proprietary method for extracting and, replicating dermal sheath cup cells, with the goal of developing a safe minimally invasive procedure for inducing natural hair growth in men and women suffering from various types of hair loss. The procedure has shown promise in pre-clinical trials, based on tissue engineering and laboratory models.
Translating Findings Into a Potential Hair-Loss Solution

Based at established universities in Canada and Germany, RepliCel’s scientific founders and research scientists have studied immunology, hair biology and hair growth for more than two decades. This respected team has developed a strong scientific understanding of the mechanisms underlying alopecia.
RepliCel’s current research activity is aimed at translating the scientific discoveries made by research scientists Drs. Kevin McElwee and Rolf Hoffmann. The scientists found that dermal sheath cup-derived cells induced the formation of new hair follicles in purpose-bred mice. The study suggested that dermal sheath cup cells were the reservoir of mesenchymal stem cells that were responsible for the continued cycling of the hair follicle, as well as neogenesis of new hair follicles.

This discovery provided the basis for patent applications beginning in 2003. Patents are now issued in Europe and Australia and are pending in the US, Canada, and Japan.
To learn more please read our scientist’s published paper in The Journal of Investigative Dermatology http://www.nature.com/jid/journal/v121/n6/full/5602058a.html

The procedure is now undergoing further rigorous study to establish safety and determine effectiveness. The first human clinical trial (Phase I/IIa) began in the country of Georgia in December 2010. Further clinical trials are planned for 2012 in European and/or North America.
Human clinical trials are now underway to translate RepliCel’s fundamental scientific findings into a safe and effective minimally invasive solution for treating androgenetic alopecia and other forms of hair loss in men and women.
There’s a lot of amazing things going on with REPCF so I'll go straight to the point to keep it from getting too confusing. The potential of this company is enormous, since its technology seems like it is in huge demand today!
That means REPCF stays diverse and isn't as vulnerable to the up and down swings of one industry.
This is a company that has found a new way to make huge benefit for both men and women! This new hair loss recovery technology could be far more efficient, and this may make traders go absolutely insane for REPCF causing some potentially enormous gains.
Their site has a great video explaining it and a lot of good info: http://www.replicel.com/
REPCF looks like the hot play for Tuesday morning!
Watch it very closely.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent REPCF News